Please assess the completion status of the following clinical trial:

Trial Title: Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for elective primary hip replacement~* Age 18 years or over~* Written informed consent obtained~Exclusion Criteria:~* Documented history or considered at increased risk of venous thromboembolism~* Subjects considered at increased risk of bleeding~* Surgery planned for contralateral hip at the same time or within 10 weeks after enrolment~* Concomitant use of anticoagulants/ antiplatelet agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).